Dimensional Fund Advisors LP Acquires 1,579,117 Shares of Pfizer Inc. $PFE

Dimensional Fund Advisors LP lifted its stake in Pfizer Inc. (NYSE:PFE) by 4.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,335,531 shares of the biopharmaceutical company’s stock after buying an additional 1,579,117 shares during the quarter. Dimensional Fund Advisors LP owned about 0.64% of Pfizer worth $925,109,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Rock Point Advisors LLC raised its stake in Pfizer by 31.5% during the 3rd quarter. Rock Point Advisors LLC now owns 123,667 shares of the biopharmaceutical company’s stock worth $3,151,000 after acquiring an additional 29,658 shares during the period. Symphony Financial Services Inc. increased its stake in shares of Pfizer by 10.2% in the third quarter. Symphony Financial Services Inc. now owns 22,494 shares of the biopharmaceutical company’s stock worth $573,000 after purchasing an additional 2,083 shares in the last quarter. Griffith & Werner Inc. bought a new stake in shares of Pfizer during the 3rd quarter valued at $3,452,000. Richard C. Young & CO. LTD. lifted its stake in shares of Pfizer by 0.6% during the 3rd quarter. Richard C. Young & CO. LTD. now owns 446,417 shares of the biopharmaceutical company’s stock valued at $11,375,000 after buying an additional 2,741 shares in the last quarter. Finally, Picton Mahoney Asset Management bought a new position in Pfizer in the 3rd quarter worth $5,115,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 2.4%

PFE stock opened at $26.60 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The stock has a market capitalization of $151.25 billion, a price-to-earnings ratio of 19.56 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm’s fifty day simple moving average is $26.20 and its two-hundred day simple moving average is $25.44.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. Pfizer’s payout ratio is 126.47%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: PF-07328948 kidney-function Phase 1 progress — Pfizer updated an ongoing study that management says supports long‑term pipeline value, reinforcing future R&D upside. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones broaden non‑COVID revenue path — Phase 3 PADCEV + Keytruda data and a full FDA approval for a BRAFTOVI regimen are material near‑term clinical wins that boost recurring oncology revenue prospects. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Dividend/defensive narrative supports demand — MarketBeat highlights Pfizer’s 6%+ yield and defensive appeal amid volatility, which can attract income‑seeking flows into PFE. The Dividend Safe Harbor: 2 Stocks to Watch
• Positive Sentiment: Analyst upgrade — Argus raised Pfizer to Buy with a $35 target, signaling upside from current levels and likely supporting positioning by discretionary investors. Benzinga coverage of Argus upgrade
• Neutral Sentiment: AI adoption in manufacturing — A market report cites Pfizer among majors integrating AI (predictive maintenance, quality control). It’s a positive long‑term efficiency story but not an immediate revenue catalyst. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: “Quiet cash comeback” narrative — Commentary on improving cash generation supports the valuation case, but it’s an incremental theme rather than a single price mover. Pfizer’s Quiet Cash Comeback
• Negative Sentiment: Zumrad EMA filing withdrawn — Pfizer pulled its Zumrad application in Europe, a clear regulatory setback that removes a near‑term approval pathway and can pressure sentiment. Pfizer withdraws Zumrad EMA filing
• Negative Sentiment: CEO flags issues with FDA vaccine leadership — Public criticism of the FDA’s vaccine leadership introduces regulatory uncertainty and could complicate future review processes or timelines. Pfizer CEO flags issues with FDA’s vaccine leadership

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Wolfe Research set a $24.00 price target on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Bank of America lowered their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. UBS Group assumed coverage on Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Finally, Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.05.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.